MLN3126

MLN3126 (MLN 3126, MLN-3126) is a potent, selective, orally available CCR9 antagonist with IC50 of 6.3 nM (CCL25-induced calcium mobilization); shows no significant antagonistic activity for other 12 chemokine receptors (CCR1, -2b, -4, -6, -7, -8, -10,CX3CR1, CXCR1, -2, -3 and -4) at 10 uM; dose dependently inhibits CCL25-induced chemotaxis of mouse thymocytes (IC90=1.8 uM); ameliorates inflammation in a T cell mediated mouse colitis model. Other Indication Phase 1 Discontinued

References 1. Igaki K, et al. Int Immunopharmacol. 2018 Jul;60:160-169. 2. Narita N, et al. Drug Metab Dispos. 2018 Mar;46(3):204-213. View Related Products by Target Chemokine Receptor (CCR and CXCR) Other Indication